Krystal Biotech underperformed the market so far this year as of August 4, 2025.
1 report, 1 independent
Updated Aug 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Krystal Biotech underperformed the market so far this year as of August 4, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Krystal Biotech, Inc.
biotechnology company
Nothing else this week.
Related events
- Krystal Biotech, Inc. and Palvella Therapeutics, Inc. were compared based on investment metrics.
- Krystal Biotech stock is seeing increased institutional investment activity, with related filings made on the SEC regarding its trading on the Nasdaq exchange.
- Insider sales of Krystal Biotech stock were disclosed to the SEC by executives.
Coverage
Newest first; wire copies grouped- ZacksKrystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.08 per